An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 11 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 10 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 10 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.